These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2566790)

  • 1. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness.
    Pepin J; Milord F; Guern C; Mpia B; Ethier L; Mansinsa D
    Lancet; 1989 Jun; 1(8649):1246-50. PubMed ID: 2566790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.
    Pépin J; Milord F; Khonde AN; Niyonsenga T; Loko L; Mpia B; De Wals P
    Trans R Soc Trop Med Hyg; 1995; 89(1):92-7. PubMed ID: 7747321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Arsenical-induced encephalopathy during the treatment of African trypanosomiasis. Apropos of a case with a favorable outcome].
    Pialoux G; Kernbaum S; Vachon F
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):555-6. PubMed ID: 3197251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.
    Pépin J; Milord F; Khonde A; Niyonsenga T; Loko L; Mpia B
    Trans R Soc Trop Med Hyg; 1994; 88(4):447-52. PubMed ID: 7570842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complications observed in the treatment of trypanosomiasis in the Congo].
    Ginoux PY; Bissadidi N; Frezil JL
    Med Trop (Mars); 1984; 44(4):351-5. PubMed ID: 6521632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of prednisolone as a routine adjunct to the treatment of T. rhodesiense.
    Foulkes JR
    J Trop Med Hyg; 1975 Apr; 78(4):72-4. PubMed ID: 1152100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness.
    Pepin J; Milord F; Guern C; Schechter PJ
    Lancet; 1987 Dec; 2(8573):1431-3. PubMed ID: 2891995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis.
    Pepin J; Milord F
    Trans R Soc Trop Med Hyg; 1991; 85(2):222-4. PubMed ID: 1887477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.
    Burri C; Nkunku S; Merolle A; Smith T; Blum J; Brun R
    Lancet; 2000 Apr; 355(9213):1419-25. PubMed ID: 10791526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
    Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
    J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An alternative form of melarsoprol in sleeping sickness.
    Kennedy PG
    Trends Parasitol; 2012 Aug; 28(8):307-10. PubMed ID: 22704910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adrenaline in the prevention and treatment of adverse effects of arsobal therapy. Apropos of 776 cases of human African trypanosomiasis caused by T. gambiense in the Health Service of Fontem (U.R. Cameroon)].
    Sina GC; Triolo N; Cramet B; Suh Bandu M
    Med Trop (Mars); 1982; 42(5):531-6. PubMed ID: 7154902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological aspects of human African trypanosomiasis (T. b. gambiense) with particular reference to reactive arsenical encephalopathy.
    Haller L; Adams H; Merouze F; Dago A
    Am J Trop Med Hyg; 1986 Jan; 35(1):94-9. PubMed ID: 3946740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].
    Eozenou P; Jannin J; Ngampo S; Carme B; Tell GP; Schechter PJ
    Med Trop (Mars); 1989; 49(2):149-54. PubMed ID: 2507863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis.
    Pépin J; Mpia B
    Trans R Soc Trop Med Hyg; 2006 May; 100(5):437-41. PubMed ID: 16483622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melarsoprol and reactive encephalopathy in Trypanosoma brucei rhodesiense.
    Arroz JO
    Trans R Soc Trop Med Hyg; 1987; 81(2):192. PubMed ID: 3617176
    [No Abstract]   [Full Text] [Related]  

  • 17. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
    Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA
    Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for second-stage human African trypanosomiasis.
    Lutje V; Seixas J; Kennedy A
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD006201. PubMed ID: 23807762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in sleeping sickness therapy.
    Van Nieuwenhove S
    Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for second-stage Human African trypanosomiasis.
    Lutje V; Seixas J; Kennedy A
    Cochrane Database Syst Rev; 2010 Aug; (8):CD006201. PubMed ID: 20687080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.